Stryker (NYSE:SYK – Get Free Report) had its price objective lowered by investment analysts at Barclays from $375.00 to $365.00 in a report issued on Friday, Benzinga reports. The firm presently has an “overweight” rating on the medical technology company’s stock. Barclays‘s target price would suggest a potential upside of 23.81% from the stock’s current price.
Several other equities analysts also recently commented on the company. TD Cowen lowered their price objective on Stryker from $355.00 to $298.00 and set a “hold” rating on the stock in a research report on Tuesday, September 22nd. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Canaccord Genuity Group cut shares of Stryker from a “buy” rating to a “hold” rating and lowered their target price for the stock from $385.00 to $300.00 in a research note on Friday. BTIG Research reduced their target price on shares of Stryker from $316.00 to $304.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Citigroup reiterated a “market outperform” rating on shares of Stryker in a report on Friday. Seventeen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average target price of $360.08.
Check Out Our Latest Research Report on Stryker
Stryker Stock Down 5.4%
Shares of Stryker stock traded down $16.94 on Friday, reaching $294.81. The company’s stock had a trading volume of 2,812,019 shares, compared to its average volume of 2,455,312. The firm’s fifty day simple moving average is $293.56 and its two-hundred day simple moving average is $324.86. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $113.08 billion, a price-to-earnings ratio of 30.50, a P/E/G ratio of 1.96 and a beta of 0.78. Stryker has a 52 week low of $267.00 and a 52 week high of $389.33.
Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a return on equity of 23.63% and a net margin of 14.43%. The company had revenue of $6.52 billion during the quarter, compared to analysts’ expectations of $6.62 billion. During the same quarter in the prior year, the business posted $3.19 EPS. The company’s revenue for the quarter was up 7.6% compared to the same quarter last year. Equities analysts anticipate that Stryker will post 14.93 earnings per share for the current year.
Insider Buying and Selling
In related news, insider Debra King sold 826 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the transaction, the director owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. This trade represents a 11.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 351,267 shares of company stock valued at $118,197,701 in the last three months. 4.60% of the stock is owned by corporate insiders.
Institutional Trading of Stryker
Hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp boosted its holdings in shares of Stryker by 1.2% in the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock valued at $4,903,772,000 after buying an additional 183,400 shares in the last quarter. Wellington Management Group LLP boosted its stake in Stryker by 0.6% in the second quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock valued at $2,571,357,000 after acquiring an additional 45,478 shares in the last quarter. Bank of America Corp DE purchased a new position in shares of Stryker during the second quarter worth about $1,404,284,000. Royal Bank of Canada boosted its position in shares of Stryker by 6.5% in the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after purchasing an additional 199,863 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Stryker by 21.8% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock worth $846,723,000 after buying an additional 481,175 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.
Key Headlines Impacting Stryker
Here are the key news stories impacting Stryker this week:
- Positive Sentiment: Third-quarter revenue increased approximately 7.6% to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also highlighted strength in the MedSurg business, margin improvement and continued investment in surgical robotics. Stryker reports third quarter 2026 operating results
- Neutral Sentiment: Several analysts remain constructive, but lowered their expectations: BTIG Research reduced its target to $304 while keeping a Buy rating, and Citizens JMP cut its target to $390 while retaining Market Outperform. Canaccord Genuity downgraded the stock to Hold and lowered its target to $300, signaling more limited near-term upside. Stryker analysts cut their forecasts
- Negative Sentiment: Quarterly adjusted EPS of $3.52 missed the roughly $3.55–$3.56 consensus, and revenue of $6.52 billion fell short of the $6.62 billion estimate. The company cited softer joint-replacement demand, manufacturing and vascular supply disruptions, and lingering operational effects from its cybersecurity incident. SYK Q3 earnings call highlights
- Negative Sentiment: Stryker cut its 2026 organic sales-growth forecast to 6.5%–7.0% from 8.3%–9.3% and reduced adjusted EPS guidance to $14.80–$14.90 from $14.95–$15.10. The reset, combined with a new CEO taking over amid the challenges, has increased uncertainty about the company’s 2027 starting point. Stryker lowers outlook after third-quarter profit falls
Stryker Company Profile
Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.
The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.
Featured Stories
- Five stocks we like better than Stryker
- Microsoft Earnings Expose a Growing Divide in the Magnificent 7 AI Trade
- Silicon Shock: Intel’s 25% Valuation Reset
- Advanced Micro Devices’ Meta Platforms Partnership Goes Beyond a $1 Billion Investment
- Chipotle’s $32 Floor: Is a Major Stock Rebound Coming?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
